Introduction: Haemoglobin A 1c (HbA 1c ) is considered to be the gold standard for the follow-up of glycaemic control in patients with diabetes mellitus and is also a diagnostic tool. Accordingly, reliable and efficient methods must be used for its quantification. Roche Diagnostics have recently adapted the Tina-quant® HbA 1c Third Generation immunoassay on a fully dedicated analyser, the Cobas c513, which allows a high throughput of up to 400 samples per hour. The present article deals with the evaluation of the analytical performances of this system which has been recently introduced to the market. 
Introduction
The term haemoglobin A 1c (HbA 1c ) is commonly used to describe the major fraction of glycated haemoglobin in blood, which results from the non-enzymatic binding of glucose on the N-terminal valine residues of haemoglobin β chains. Haemoglobin A 1c is considered the best marker for the monitoring of diabetic patients because its evaluation provides retrospective information on the glycaemic balance of patients for the past 6-8 weeks (1) . Moreover, elevated HbA 1c values are associated with the development of long-term complications in type 1 and type 2 diabetes (2-4). The number of countries recommending the use of HbA 1c for the diagnosis of diabetes, with a threshold value of 48 mmol/mol (6.5%), has risen in recent years (5, 6) . The use of HbA 1c for such diagnostic purposes requires reliable, accurate, and robust analytical methods in order to avoid misdiagnosis, which could result in high unwarranted expenditure on patient care in the case of over-diagnosis. Consequently, available diagnostic methods must be traceable to internationally accepted reference methods in order to improve the overall comparability of methods and assessment of their quality performance (7, 8) .
The evaluation of HbA 1c values may be performed using a number of methods based on various principles, ranging from separative methods (e.g. ionexchange chromatography and capillary electrophoresis) to immunological assays. Due to both, the increasing number of patients with diabetes worldwide and the expanded use of HbA 1c for diabetes diagnosis, the need for HbA 1c assessment is constantly increasing. To meet these needs, manufacturers are now offering robust analytical solutions with higher throughput than previously available, particularly in laboratory settings.
Roche Diagnostics have recently adapted the Tina-quant® HbA 1c Third Generation immunoassay on a fully dedicated analyser, the Cobas c513, which allows a sample throughput of up to 400 samples per hour. The present study was performed to evaluate the analytical performance of this system, with a focus on comparison with two routine high-performance liquid chromatography (HPLC) systems (D-100 and Variant II analysers from Bio-Rad Laboratories), the accuracy and precision of the method, the interference of the most frequent haemoglobin (Hb) variants, and the usability of the system.
Materials and methods

Materials
The analyser and reagents used for this evaluation were provided by Roche Diagnostics (Mannheim, Germany) and were used according to manufacturer's instructions.
Cobas c513 analyser
Cobas c 513 is a fully dedicated HbA 1c assay analyser with a high throughput, owing the use of ready-to-use reagents in a large kit size. This analyser also makes use of minimized operator intervention; from sample registration to result delivery, and a closed-tube sampling function. Onboard stability of the reagents is 4 weeks. The analyser must be calibrated every month or at each change of the reagent lot number.
HbA 1c determination utilizes the Tina-quant® Third Generation assay, which is based on a turbidimetric inhibition immunoassay (TINIA) for haemolysed whole blood. The first step is the preparation of the blood haemolysate using a detergent-containing reagent. The second step is the spectrophotometric measurement of total Hb in the haemolysate, converted to a stable derivative at 376 nm. In parallel, HbA 1c reacts with the anti-HbA 1c antibody to form soluble antigen-antibody complexes. Finally, the polyhaptens contained in the reagent react with excess anti-HbA 1c antibodies and form an insoluble antibody-polyhapten complex, which is measured by turbidimetry at 340 nm (the higher the HbA 1c concentration, the lower the turbidity). The output of this method is linear from 23 mmol/ mol (4.3%) to 196 mmol/mol (20.1%).
Samples
For the comparison study, blood samples collected in ethylenediaminetetraacetic acid (EDTA)-containing tubes (Sarstedt, Nümbrecht, Germany) received by the Bio-Paris-Ouest laboratory for HbA 1c measurement, were selected following analysis with the D-100 system. Samples were then shipped to the Reims University Hospital laboratory at 2-8 °C within the 48 hours, for HbA 1c measurement with the Cobas c513 system. For the precision study, blood samples were collected in EDTA-containing tubes (BD Vacutainer, Le Pont de Claix, France) and sent to the laboratory for routine HbA 1c assay. No additional samples were necessary for this study, and no samples were stored after the assays. Quality control (QC) samples (PreciControlA1c Norm and PreciControlA1c Path), blood samples with International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)-assigned values and blood samples with Hb variants were provided by Roche Diagnostics.
Methods
Precision study
The precision study was performed according to Clinical & Laboratory Standards Institute (CLSI) EP05-A3 protocol (9). Quality controls (two levels) and patient samples (four levels covering the analytical range) were analysed in duplicate, twice daily for 21 days (i.e. 84 determinations). Samples were aliquoted and stored at -80 °C to avoid freezing/thawing cycles. The analyser was calibrated twice during the precision study and the same reagent and calibrator lot numbers were used. The acceptance criteria for precision were total imprecision coefficients of variation (CVs) lower than 2% as recommended in the literature (6) .
Comparison study
The comparison study was performed according to an internal protocol. For that purpose, samples (N = 100) were assayed using Cobas c513 and two routinely used HPLC analysers (Variant II equipped with a Dual Kit and D-100, Bio-Rad Laboratories, Hercules, USA). Haemoglobin A 1c values were compared by Passing Bablok regression and Bland-Altman analyses, using samples with HbA 1c values distributed across the linearity range (10, 11) . Samples with Hb variants or elevated values of carbamylated Hb (cHb) or labile HbA 1c were excluded from the comparison study. All comparative assays were performed within a 48 hour-period, and samples were kept at + 4 °C until analysis. The interpretation of data was based on the results of Passing Bablok regression analysis, which allows the determination of constant and proportional errors, and Bland-Altman analysis in which the proportion of outliers had to be lower than 5%.
Accuracy
Eight external assurance quality samples with IFCCassigned values obtained from the European Reference Laboratory for Glycohemoglobin (Winterswijk, The Netherlands) were analysed in triplicate using the Cobas c513 analyser. Absolute and relative biases between the target and the obtained values were calculated to evaluate the accuracy of the method. The acceptance criteria for accuracy were based on those used for the sigma-metrics model calculation, in which absolute biases should be lower than 5 mmol/mol in IFCC units (12) .
Interferences
The influence of bilirubin and triglycerides on HbA 1c quantification was studied by mixing washed red blood cells with various dilutions of hyperbilirubinemic or triglyceride-rich plasmas to obtain bilirubin and triglyceride concentrations reaching 352 μmol/L and 20.6 mmol/L, respectively.
The influence of the most common Hb variants (Hb AC, AD, AE, AS) on HbA 1c measurement was determined by analysing samples containing Hb variants (N = 10 per variant) with various concentrations of HbA 1c . Each sample had assigned target values using a comparison method (IFCC calibrated boronate affinity chromatography method, Premier Hb9210) which is known to be unaffected by the presence of Hb variants (assignment performed at the European Reference Laboratory for Glycohemoglobin, The Netherlands). In parallel, 40 HbAA samples covering the same HbA 1c range as variant samples were assayed in order to assess the relative deviation of variant samples compared to normal ones. Haemoglobin AA results were used for the calculation of a regression line, any difference exceeding ± 10% with respect to this line in Hb variant samples was considered clinically significant (13) .
Influence of red blood cell sedimentation
In order to determine the impact of red blood cell sedimentation on the measurement of HbA 1c , ten samples were assayed after 1h, 2h, 5h and 24h incubation periods at 4 °C or at room temperature. Tubes were not shaken during this incubation time so as to not disturb the blood cell sedimentation process. After the 24h incubation time, all samples were homogenized and analysed again. Values were compared with HbA 1c values obtained on agitated samples before starting the incubation period. The acceptance criteria were based on relative biases which had to be close to zero and a mean relative bias lower than 5%.
Statistical analyses
Statistics were performed using Graph-Pad Prim 6.0 and R softwares.
Results
Precision study
For QC samples, the CVs were lower than 1 
Accuracy
The relative biases ranged from -0.2% to + 3.4%; the mean relative bias was + 1.6% for HbA 1c values expressed in IFCC units (+ 1.2% for values expressed in NGSP units) ( Table 2 ). All absolute biases were lower than 3 mmol/mol and the mean absolute bias in IFCC units was + 1.1 mmol/mol (+ 0.10% HbA 1c in NGSP units). For these two comparison studies, the cusum test for linearity indicated no significant deviation (P > 
Comparison study
Interferences
No analytical interferences of bilirubin and triglycerides were noted for concentrations reaching 352 μmol/L and 20.6 mmol/L, respectively ( Table 3) . The relative biases, calculated from HbA 1c values expressed in mmol/mol, ranged from -1.4% to + 1.6% for bilirubin, and between -4.0% to + 0.8% for triglycerides.
For testing the interference of Hb variants, ten blood samples containing the most frequent variants in their heterozygous forms (Hb AC, AD, AE, AS) were analysed using Cobas c513. HbA 1c values were compared with assigned values obtained with a boronate affinity chromatography method, which is recognized to not be affected by the presence of Hb variants. First, the two methods were compared using 40 HbAA samples which were used to establish a linear regression line around which an interval of ± 10% was defined (Figure 2 
Influence of red blood cell sedimentation
The influence of blood cell sedimentation was evaluated by analysing several samples over a 24h sedimentation period. At each time point, the mean relative biases were calculated using the values obtained at time zero as a reference. The results shown in Figure 3 demonstrate that the relative biases did not exceed 5%. The biases were less important when samples have been stored at 4 °C instead of room temperature. The biases were close to 0% when the samples were agitated shortly before analysis at the end of the sedimentation time.
Usability and ergonomics
The Cobas c513 has a high throughput of up to 400 tests per hour on whole blood samples. It allows closed-tube sampling and offers the possibility to work on 10 µL whole blood-capillary straws, which are loaded and remain in the Sarstedt Tinaquant tubes containing 1000 µL of haemolysate. The system requires minimal daily manual maintenance. Moreover, automatic maintenance may be launched during scheduled instrument wake-up, allowing a quicker start-up time. No breakdowns occurred during the evaluation and the availability of tele-maintenance provided training and sup- port on the instrument. Other advantages of this instrument are the availability of automatic identification of tube size and caps, labelling of reagent cassettes by radio-frequency identification, and automatic download of information such as calibrator and QC values, which reduces the need for manual entries.
Discussion
Haemoglobin A 1c is an essential biomarker for monitoring the glycaemic status of patients with diabetes mellitus and is becoming increasingly used for diabetes diagnosis. Its use as a diagnostic tool requires the use of reliable, accurate, and robust analytical methods to avoid misdiagnosis and associated healthcare complications. Fortunately, important advances have emerged in recent years regarding HbA 1c assessment, in particular through the global standardization of HbA 1c assays and the development of more systematic external quality assurance schemes driven by the IFCC working group and the task force for HbA 1c standardization (14) . This process has improved the homogeneity of HbA 1c assessment and reduced the imprecision of the associated methods, thus improving their reliability and in turn facilitating the use of HbA 1c
for the screening of subjects with diabetes. All methods newly introduced to the market must now be traceable and linked to the IFCC reference method (7).
The ever-increasing number of patients with diabetes worldwide is associated with a greater requirement for HbA 1c assays. To meet this demand, manufacturers have focused on optimizing their analytical systems in recent years to develop high throughput solutions that retain the technical performances required for reliable HbA 1c determination. To this end, Roche Diagnostics have recently developed a new system, the Cobas c513 analyser, which meets the aforementioned criteria and for which the Tina-quant® Third Generation immunoassay has been adapted.
Precision studies of this system yielded promising results, whereby total imprecision CVs did not exceed 1.1% in NGSP units and 1.7% in IFCC units, consistent with the current recommendations for such systems (6, 8) . As widely acknowledged in the literature, CVs calculated from values expressed in IFCC units are higher than those obtained from NGSP units (15) . mean relative bias of + 1.6% and absolute biases lower than 5 mmol/mol demonstrating a good traceability of this method to the IFCC reference system (12) . The Cobas c513 analyser was compared with two routine HPLC systems based on the same chromatographic separation principles, comprising an older system with limited throughput (Variant II, dual kit, BioRad Laboratories) and a more recent system (D-100 system, BioRad Laboratories) (16 Since the analyser does not stir tubes before sampling, we also evaluated the influence of red blood cell sedimentation on the HbA 1c assay. The sedimentation test showed that, over a 24h period, HbA 1c values remained close to initial values, with relative biases of less than 5%. However, when this test was carried out on tubes kept at 4°C between each measurement, the biases were even lower and came close to zero when the tubes had been shaken after 24h of sedimentation. These results suggest that, even if these differences are not significant, it is advisable to shake the tubes before loading them on the device.
The results of this evaluation are consistent with two other recently published studies, which showed that the Cobas c513 method was comparable to other HbA 1c methods and demonstrated that it fulfilled the criteria for becoming a secondary reference measurement procedure (13, 17) .
This study has some limitations. For example, the comparison study was carried out using two HPLC systems with similar methodological principles. A comparison with other types of HbA 1c assays (e.g. capillary electrophoresis or an enzymatic method) could further improve our understanding, although such comparisons have already been described by other authors (13, 17) . A further limitation of the present study is that the interference of Hb variants would ideally be analysed in a larger number of samples.
In conclusion, the Cobas c513 analyser exhibits good analytical performance for the measurement of HbA 1c at high throughput, making it a reliable system for routine practice in clinical chemistry laboratories performing large-scale HbA 1c assays.
